Gastric Sleeve vs Ozempic: Comparing the Numbers Fairly
A drug and an operation land a sandwich apart on weight loss, and the fine print decides what that is worth.

A network meta-analysis of 23 randomized trials, covering 14,293 people, concluded that a weekly drug and a stomach operation produce almost exactly the same weight loss: a mean 21.3% of total body weight for tirzepatide at 10 or 15 mg, against 21.1% for sleeve gastrectomy. Those are a pharmaceutical product and a surgery, and they finished about two-tenths of a point apart.
If you typed gastric sleeve vs ozempic, that is the closest thing to a straight answer this evidence offers, and it comes with two problems. First, the drug in that comparison is tirzepatide, not the semaglutide sold as Ozempic. The facts here contain no clean head-to-head of the sleeve against semaglutide on weight loss, so that exact question is not settled. Second, “about the same” describes roughly the first year or two. The drug evidence here runs to 72 weeks in trials and three years in one retrospective study. The sleeve has ten-year data, and its numbers move over those ten years.
Gastric sleeve vs Ozempic: reading the best sentence one clause at a time
Here is the sentence, from the meta-analysis titled “Comparison of pharmacotherapies for obesity with sleeve gastrectomy.” It says tirzepatide 10 or 15 mg produced a mean 21.3% total body weight loss, “statistically equivalent to sleeve gastrectomy.” Let’s read it like a contract, because it is about to be treated like one.
“A network meta-analysis.” A network meta-analysis is basically a way of ranking treatments that were not all tested against each other in the same trial, by linking them through the trials that do exist. It is a clever method. It is also a method for comparing people who never met.
“Of 23 randomized controlled trials (14,293 participants).” That is a lot of people. It does not say how many of them had a sleeve and how many took a drug, and drug trials tend to be big while surgical trials tend to be small (the Oseberg surgery trial, for instance, randomized 109 people in total). So the 14,293 is in some sense mostly a drug number, attached to a surgery comparison.
“Tirzepatide 10 or 15 mg.” Not the 5 mg dose, and not Ozempic. The sentence chose its competitor carefully. It’s fine.
“Statistically equivalent.” Here is the jargon. Translated flatly: the researchers could not tell the two apart with the data they had. That is not the same as the two being the same.
The two-tenths of a point, and the parentheses around it
Look at the gap: 21.3% versus 21.1%. That is 0.2 percentage points. For a made-up patient who weighs 120 kg, two-tenths of a percent of body weight is 240 grams, which is roughly a sandwich. Two entirely different interventions, one involving anesthesia and one involving a pharmacy, landed a sandwich apart. It is a beautiful number.
Then you read the parentheses, which is where the contract keeps its exceptions. The drug’s 95% confidence interval runs from 17.3% to 25.2%. The sleeve’s runs from 14.2% to 28.0%. (I write about this sort of thing for a living and still had to look at those parentheses twice.) The sleeve’s range is nearly 14 points wide. The headline gap is 0.2.
So the honest reading is something like this: the drug is fairly well measured, the sleeve is measured with a garden hose, and the two estimates overlap. You can picture the surgeons at the conference: “Hey, in fairness, our interval is wider than yours.” That is not quite the win it sounds like.
And the sentence has a rival. A 2026 systematic review comparing incretin drugs with surgery said tirzepatide 15 mg “approached but did not match” sleeve gastrectomy weight-loss benchmarks at 72 weeks. Same drug, same operation, a different reading of the same rough terrain. I would rather not think about what the marketing departments have planned for the phrase “statistically equivalent to surgery.”
Total weight, excess weight, and other units of loss
Part of why the sleeve’s range is so wide is that sleeve results really do vary. The Oseberg trial found 17.2% total body weight loss at five years. A German trial of banded versus non-banded sleeves found 27.4% at five years for the standard sleeve. One review puts the sleeve at 25 to 30% total body weight loss at two to five years. Those are all the same operation.
Then there are the units. Some studies report total weight loss, the share of your whole body weight that went away. Others report excess weight loss, the share of the weight above some target that went away. The same review gives the sleeve 60 to 70% excess weight loss and 25 to 30% total. Those describe the same patients (who were presumably not consulted on the choice of denominator).
This is how you end up with headlines where one treatment “loses 60%” and another “loses 21%” and they are basically identical. It is like comparing one quarterback’s completion percentage to another’s yards per game and announcing a winner. Units matter here. They matter a lot.
Drug trials mostly report total weight loss, which is the fairer unit for this comparison. SURMOUNT-1, the big tirzepatide trial, reported 22.5% mean body weight loss at 15 mg, with 36.2% of that group losing at least a quarter of their weight. Put that next to a sleeve’s 60 to 70% excess weight loss and the drug looks small. Put it next to the sleeve’s total weight loss and it looks like a peer.
How long the numbers last
This is where the comparison stops being symmetrical. At ten years, a long-term review gives a weighted mean of 24.4% total weight loss for the sleeve. The SLEEVEPASS trial found 43.5% excess weight loss for the sleeve at ten years (versus 51.9% for gastric bypass). So the sleeve holds a meaningful amount of its result for a decade, while also slipping.
The slipping has a name. One paper says up to half of sleeve patients may need conversion surgery because of “insufficient weight loss, weight recurrence, or complications.” Weight recurrence is the official phrase. It means the weight came back. A ten-year Polish study found revision procedures in 24.3% of sleeve patients.
For the drugs, the evidence here does not run ten years, so the ten-year comparison is not settled. There is one odd small data point. A prospective study of endometrial cancer patients found that by two years, weight regain occurred in 55.6% of the semaglutide group and 66.7% of the sleeve group, against 14.3% for a structured lifestyle program called DEAR (Diet, Exercise, Accompany and Refresh). The lifestyle program won. That is a small, specific population, and it is one study. But it is a reminder that “durable” is a claim each treatment has to earn separately.
And here is the made-up scenario this all invites. Imagine a patient who decides purely on the 0.2-point gap, picks the drug, then reads the confidence intervals and switches to surgery, then reads the ten-year revision rates and switches back, then reads the DEAR program results and buys running shoes. This patient has now lost zero weight and read four meta-analyses. Lol.
What happens when the sleeve is not enough
The most direct drug-versus-surgery comparison in these facts is not about first-time patients at all. It is about people who already had a sleeve and did not get the result they wanted. A multicenter retrospective study of 4,901 such patients compared converting the sleeve to gastric bypass (3,004 people) with adding a GLP-1 drug (1,897 people). At three years, conversion produced 26.1% total body weight loss and the drug produced 13.7%.
The two groups started at the same weight: 242.3 kg versus 242.8 kg, with a p-value of 0.993. That is about as “not different” as two groups can be (statisticians rarely get a number this tidy outside a textbook). The study is retrospective, so the patients were not randomly assigned, and people who choose a second operation may differ from people who choose a prescription in ways a weight number does not catch. I don’t know how much that matters. The study cannot fully say either.
So the pattern, as far as these facts go, is roughly this. In the first year or two, the best drug and the sleeve look close, though the two reviews disagree on whether close means equal. Over ten years the sleeve has evidence and the drugs mostly do not. And after a sleeve that underperforms, another operation outdid the drug by about double over three years.
The surgery has a ten-year number and the drug has a 72-week number, and most of the argument is about the years in between.
Sources
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
- Banded Versus Non-banded Sleeve Gastrectomy: 5-Year Results of a 3-Year Randomized Controlled Trial
- Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study
- Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
- Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
- A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
- Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review
- Long-term outcomes of metabolic bariatric surgery: a 10-Year multicenter retrospective study in Poland (BARI-10-POL)
- Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
- Scholars@Duke publication: Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.
- Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial
- Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study
- Tirzepatide Once Weekly for the Treatment of Obesity
- Lilly's SURMOUNT-1 results published in The New ...
Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.